Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?

Moser S, Bacher U, Jeker B, Mansouri Taleghani B, Betticher D, Ruefer A, Egger T, Novak U, Pabst T.

Hematol Oncol. 2019 Sep 4. doi: 10.1002/hon.2673. [Epub ahead of print] No abstract available.

PMID:
31483507
2.

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C; Swiss Group for Clinical Cancer Research SAKK.

Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2.

3.

Chitosan-based films with incorporated supercritical CO2 hop extract: Structural, physicochemical, and antibacterial properties.

Bajić M, Jalšovec H, Travan A, Novak U, Likozar B.

Carbohydr Polym. 2019 Sep 1;219:261-268. doi: 10.1016/j.carbpol.2019.05.003. Epub 2019 May 7.

PMID:
31151524
4.

Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia.

De Santiago de Benito A, Jeker B, Gfeller E, Porret N, Banz Y, Novak U, Bacher U, Pabst T.

Haematologica. 2019 May 23. pii: haematol.2019.216457. doi: 10.3324/haematol.2019.216457. [Epub ahead of print]

5.

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group.

Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17.

PMID:
31101627
6.

Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML.

Shumilov E, Flach J, Joncourt R, Porret N, Wiedemann G, Novak U, Gfeller E, Jeker B, Amstutz U, Pabst T, Bacher U.

Leuk Lymphoma. 2019 Apr 18:1-3. doi: 10.1080/10428194.2019.1585838. [Epub ahead of print] No abstract available.

PMID:
30998101
7.

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM.

Lancet Oncol. 2019 May;20(5):649-662. doi: 10.1016/S1470-2045(18)30935-5. Epub 2019 Apr 1.

8.

Improved survival rates of AML patients following admission to the intensive care unit.

Fassbind P, Jeker B, Mueller BU, Bacher U, Zimmerli S, Endrich O, Gahl B, Novak U, Pabst T.

Leuk Lymphoma. 2019 Apr 3:1-9. doi: 10.1080/10428194.2019.1594213. [Epub ahead of print]

PMID:
30943056
9.

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.

Prediletto I, Farag SA, Bacher U, Jeker B, Mansouri Taleghani B, Brégy R, Zander T, Betticher D, Egger T, Novak U, Pabst T.

Bone Marrow Transplant. 2019 Mar 19. doi: 10.1038/s41409-019-0508-2. [Epub ahead of print] No abstract available.

PMID:
30890768
10.

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.

Amsler IG, Jeker B, Mansouri Taleghani B, Bacher U, Betticher D, Egger T, Zander T, Luethi JM, Novak U, Pabst T.

Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8. No abstract available.

PMID:
30616438
11.

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.

Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, Fiedler M, Novak U, Amstutz U, Pabst T.

Blood Cancer J. 2018 Nov 12;8(11):113. doi: 10.1038/s41408-018-0148-6. Review.

12.

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells.

Burkhard R, Keller I, Arambasic M, Juskevicius D, Tzankov A, Lundberg P, Bruggmann R, Dirnhofer S, Radpour R, Novak U.

Haematologica. 2019 Apr;104(4):766-777. doi: 10.3324/haematol.2018.201590. Epub 2018 Oct 31.

13.

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.

Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T.

Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20. No abstract available.

14.

Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia.

Alva LC, Bacher U, Seipel K, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Transfusion. 2018 Oct;58(10):2365-2373. doi: 10.1111/trf.14895. Epub 2018 Sep 10.

PMID:
30203418
15.

Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F, Bernasconi E; Swiss HIV Cohort study (SHCS).

Hematol Oncol. 2018 Dec;36(5):757-764. doi: 10.1002/hon.2536. Epub 2018 Aug 16.

PMID:
30113708
16.

Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.

Farag S, Jeker B, Bacher U, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Hematol Oncol. 2018 Oct;36(4):671-678. doi: 10.1002/hon.2546. Epub 2018 Sep 11.

PMID:
30110717
17.

Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.

Bachmann KF, Nebiker M, Johner C, Bregy R, Schaller A, Novak U, Jakob SM.

A A Pract. 2019 Feb 15;12(4):96-98. doi: 10.1213/XAA.0000000000000855.

PMID:
30052534
18.

Diagnosis and treatment of follicular lymphoma: an update.

Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2018 Jul 24;148:w14635. doi: 10.4414/smw.2018.14635. eCollection 2018. Review.

19.

Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.

Moor I, Bacher VU, Jeker B, Taleghani BM, Mueller BU, Keller P, Betticher D, Egger T, Novak U, Pabst T.

Bone Marrow Transplant. 2018 Dec;53(12):1599-1602. doi: 10.1038/s41409-018-0245-y. Epub 2018 Jun 8. No abstract available.

PMID:
29884856
20.

Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.

Gössi U, Jeker B, Mansouri Taleghani B, Bacher U, Novak U, Betticher D, Egger T, Zander T, Pabst T.

Hematol Oncol. 2018 Apr;36(2):436-444. doi: 10.1002/hon.2490. Epub 2018 Jan 24.

PMID:
29363149
21.

Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.

Cihoric N, Tsikkinis A, Vlaskou Badra E, Glatzer M, Novak U, Scherz A, Shelan M, Soldatovic I, Yojena CKK, Aebersold DM, Lössl K.

Radiat Oncol. 2017 Dec 22;12(1):202. doi: 10.1186/s13014-017-0938-1.

22.

NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.

Jeker B, Novak U, Mansouri Taleghani B, Baerlocher GM, Seipel K, Mueller BU, Bigler M, Betticher D, Luethi JM, Farese S, Ruefer A, Pabst T.

Bone Marrow Transplant. 2018 Feb;53(2):175-179. doi: 10.1038/bmt.2017.234. Epub 2017 Oct 23.

PMID:
29058701
23.

Recurrent Inflammatory Flares in HIV-Infected Patients: Consider Castleman Disease!

Jegerlehner S, Rauch A, Novak U.

J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617725094. doi: 10.1177/2324709617725094. eCollection 2017 Jul-Sep.

24.

The role of a surveillance programme for intro-ducing peripherally inserted central catheters: a 2-year observational study in an academic hospital.

Lo Priore E, Fliedner M, Heverhagen JT, Novak U, Marschall J.

Swiss Med Wkly. 2017 May 11;147:w14441. doi: 10.4414/smw.2017.14441. eCollection 2017.

25.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

26.

Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML.

Blum V, Heini AD, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Seipel K, Banz Y, Bargetzi M, Pabst T.

Bone Marrow Transplant. 2017 May;52(5):786-788. doi: 10.1038/bmt.2017.2. Epub 2017 Feb 13. No abstract available.

PMID:
28194031
27.

BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.

Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, Zander T, Betticher D, Egger T, Rauch D, Pabst T.

Ann Hematol. 2017 Mar;96(3):421-429. doi: 10.1007/s00277-016-2900-y. Epub 2016 Dec 24.

PMID:
28011985
28.

Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.

Heini AD, Berger MD, Seipel K, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, Novak U, Pabst T.

Leuk Res. 2017 Feb;53:28-34. doi: 10.1016/j.leukres.2016.12.001. Epub 2016 Dec 8.

PMID:
27978458
29.

Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.

Stettler J, Novak U, Baerlocher GM, Seipel K, Mansouri Taleghani B, Pabst T.

Leuk Lymphoma. 2017 May;58(5):1076-1083. doi: 10.1080/10428194.2016.1233542. Epub 2016 Oct 13.

30.

CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.

Juilland M, Gonzalez M, Erdmann T, Banz Y, Jevnikar Z, Hailfinger S, Tzankov A, Grau M, Lenz G, Novak U, Thome M.

Blood. 2016 Apr 7;127(14):1780-9. doi: 10.1182/blood-2015-07-655647. Epub 2016 Jan 8.

31.

HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis.

Rohner E, Wyss N, Heg Z, Faralli Z, Mbulaiteye SM, Novak U, Zwahlen M, Egger M, Bohlius J.

Int J Cancer. 2016 Jan 1;138(1):45-54. doi: 10.1002/ijc.29687. Epub 2015 Jul 28. Review.

32.

Not all facial swellings are angioedemas!

Fricker M, Dubach P, Helbling A, Diamantis E, Villiger PM, Novak U.

J Investig Allergol Clin Immunol. 2015;25(2):146-7. No abstract available.

33.

Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

Keller S, Seipel K, Novak U, Mueller BU, Taleghani BM, Leibundgut K, Pabst T.

Leuk Res. 2015 Jul;39(7):786-92. doi: 10.1016/j.leukres.2015.03.015. Epub 2015 Mar 28.

PMID:
25891070
34.

Microfluidic droplet-based liquid-liquid extraction: online model validation.

Lubej M, Novak U, Liu M, Martelanc M, Franko M, Plazl I.

Lab Chip. 2015 May 21;15(10):2233-9. doi: 10.1039/c4lc01460j.

PMID:
25850663
35.

Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.

Berger MD, Branger G, Klaeser B, Taleghani BM, Novak U, Banz Y, Mueller BU, Pabst T.

Hematol Oncol. 2016 Sep;34(3):133-9. doi: 10.1002/hon.2197. Epub 2015 Feb 17.

PMID:
25689832
36.

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.

Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM; HIV-Associated Hodgkin Lymphoma in the cART Era Study Group.

Cancer. 2015 Feb 1;121(3):423-31. doi: 10.1002/cncr.29066. Epub 2014 Sep 23.

37.

Multiple myeloma-associated amyloidoma of the sacrum: case report and review of the literature.

Klenke FM, Wirtz C, Banz Y, Keel MJ, Klass ND, Novak U, Benneker LM.

Global Spine J. 2014 Jun;4(2):109-14. doi: 10.1055/s-0033-1360724. Epub 2013 Nov 22.

38.

HHV-8 seroprevalence: a global view.

Rohner E, Wyss N, Trelle S, Mbulaiteye SM, Egger M, Novak U, Zwahlen M, Bohlius J.

Syst Rev. 2014 Feb 12;3:11. doi: 10.1186/2046-4053-3-11. Review.

39.

BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.

Burkhard R, Bhagat G, Cogliatti SB, Rossi D, Gaidano G, Pasqualucci L, Novak U.

Hematol Oncol. 2015 Mar;33(1):23-30. doi: 10.1002/hon.2132. Epub 2014 Feb 4.

PMID:
24496723
40.
41.

Mineral deposition in bacteria-filled and bacteria-free calcium bodies in the crustacean Hyloniscus riparius (Isopoda: Oniscidea).

Vittori M, Rozman A, Grdadolnik J, Novak U, Štrus J.

PLoS One. 2013;8(3):e58968. doi: 10.1371/journal.pone.0058968. Epub 2013 Mar 12.

42.

Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells.

Novak U, Basso K, Pasqualucci L, Dalla-Favera R, Bhagat G.

Br J Haematol. 2011 Nov;155(3):362-5. doi: 10.1111/j.1365-2141.2011.08841.x. Epub 2011 Aug 25.

PMID:
21883140
43.

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.

Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, Rancoita PM, De Campos CP, Forconi F, Gascoyne RD, Facchetti F, Ponzoni M, Govi S, Ferreri AJ, Mollejo M, Piris MA, Baldini L, Soulier J, Thieblemont C, Canzonieri V, Gattei V, Marasca R, Franceschetti S, Gaidano G, Tucci A, Uccella S, Tibiletti MG, Dirnhofer S, Tripodo C, Doglioni C, Dalla Favera R, Cavalli F, Zucca E, Kwee I, Bertoni F.

Blood. 2011 Feb 3;117(5):1595-604. doi: 10.1182/blood-2010-01-264275. Epub 2010 Nov 29.

44.

[Molecular biology of malignant lymphomas for non-specialists].

Novak U.

Ther Umsch. 2010 Oct;67(10):501-4. doi: 10.1024/0040-5930/a000085. Review. German.

PMID:
20886455
45.

BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.

Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, Crespo M, Shen Q, Bhagat G, Califano A, Chadburn A, Pasqualucci L, Dalla-Favera R.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11294-9. doi: 10.1073/pnas.0903854106. Epub 2009 Jun 23.

46.

The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, Pasqualucci L, Bhagat G, Bertoni F.

Blood. 2009 May 14;113(20):4918-21. doi: 10.1182/blood-2008-08-174110. Epub 2009 Mar 3.

47.

Brain tumour invasion: Many cooks can spoil the broth.

Novak U, Kaye AH.

J Clin Neurosci. 1999 Nov;6(6):455-63. No abstract available.

PMID:
18639180
48.

Differential coding potential of ADAM22 mRNAs.

Gödde NJ, D'Abaco GM, Paradiso L, Novak U.

Gene. 2007 Nov 15;403(1-2):80-8. Epub 2007 Aug 23.

PMID:
17884303
49.

Efficient ADAM22 surface expression is mediated by phosphorylation-dependent interaction with 14-3-3 protein family members.

Gödde NJ, D'Abaco GM, Paradiso L, Novak U.

J Cell Sci. 2006 Aug 15;119(Pt 16):3296-305. Epub 2006 Jul 25.

50.

Diagnosis of Burkitt lymphoma in due time: a practical approach.

Cogliatti SB, Novak U, Henz S, Schmid U, Möller P, Barth TF; Swiss Group for Clinical Cancer Research (SAKK).

Br J Haematol. 2006 Aug;134(3):294-301.

PMID:
16848772

Supplemental Content

Support Center